文献速递心脏核医学放射性药物与辐射防护

靶向趋化因子受体CCR5的炎症显像示踪剂111In-DOTA-DAPTA的研制及在ApoE-/-动脉粥样硬化小鼠模型中的初步评价

Development of an inflammation imaging tracer, 111In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE-/- atherosclerosis mouse model.
PubMed 文献 · J Nucl Cardiol · 2018-02-07

研究以CCR5拮抗剂DAPTA经DOTA偶联后标记111In,在U87-CD4-CCR5与U87-MG细胞、C57BL/6小鼠及ApoE-/-小鼠中评价其CCR5靶向性与动脉粥样硬化斑块炎症显像潜力。111In-DOTA-DAPTA放射化学纯度>98%、比活度70 MBq·nmol,细胞摄取可被DAPTA抑制,ApoE-/-小鼠斑块摄取高于C57BL/6小鼠且可被阻断剂降低,作者认为其是潜在的动脉粥样硬化炎症SPECT显像剂。

要点

  • 111In-DOTA-DAPTA放射化学纯度>98%,比活度70 MBq·nmol。
  • U87-CD4-CCR5细胞摄取显著高于U87-MG细胞,加入DAPTA后摄取降低三倍。
  • ApoE-/-小鼠斑块摄取显著高于C57BL/6小鼠,阻断后摄取降低两倍。

核心结论

  • 111In-DOTA-DAPTA特异性靶向趋化因子受体CCR5,是用于动脉粥样硬化炎症显像的潜在SPECT显像剂。

研究设计与样本

  • 研究将DOTA偶联的DAPTA用111In标记,在U87-CD4-CCR5与U87-MG细胞中进行细胞摄取研究。
  • 在C57BL/6小鼠中测定体内分布,在ApoE-/-小鼠中进行放射自显影、en face及油红O(ORO)显像研究。

主要发现

  • DOTA-DAPTA经111In标记,放射化学纯度>98%,比活度70 MBq·nmol。
  • 111In-DOTA-DAPTA表现为快速血液和肾脏清除以及高脾脏摄取。
  • U87-CD4-CCR5细胞摄取显著高于U87-MG细胞,加入DAPTA后细胞摄取降低三倍,提示摄取具有受体特异性。
  • 放射自显影显示ApoE-/-小鼠病灶摄取显著高于C57BL/6小鼠。
  • 4月龄ApoE-/-高脂饮食(HFD)小鼠使用阻断剂后示踪剂摄取较同一小鼠未使用阻断剂时低两倍,证明示踪剂对CCR5受体的特异性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemokine receptor 5 (CCR5) plays an important role in atherosclerosis. Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In. METHODS: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated DAPTA (DOTA-DAPTA) was labeled with 111In. Cell uptake studies were conducted in U87-CD4-CCR5 and U87-MG cells. Biodistribution was determined in C57BL/6 mice. Autoradiography, en face and Oil Red O (ORO) imaging studies were performed in ApoE-/- mice. RESULTS: DOTA-DAPTA was radiolabeled with 111In with high radiochemical purity (> 98%) and specific activity (70 MBq·nmol). 111In-DOTA-DAPTA exhibited fast blood and renal clearance and high spleen uptake. The U87-CD4-CCR5 cells had significantly higher uptake in comparison to the U87-MG cells. The cell uptake was reduced by three times with DAPTA, indicating the receptor specificity of the uptake. Autoradiographic images showed significantly higher lesion uptake of 111In-DOTA-DAPTA in ApoE-/- mice than that in C57BL/6 mice. The tracer uptake in 4 month old ApoE-/- high fat diet (HFD) mice with blocking agent was twofold lower than the same mice without the blocking agent, demonstrating the specificity of the tracer for the CCR5 receptor. CONCLUSION: 111In-DOTA-DAPTA, specifically targeting chemokine receptor CCR5, is a potential SPECT agent for imaging inflammation in atherosclerosis.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Wei L, Petryk J, Gaudet C, et al. Development of an inflammation imaging tracer, 111In-DOTA-DAPTA, targeting chemokine receptor CCR5 and preliminary evaluation in an ApoE-/- atherosclerosis mouse model. J Nucl Cardiol. 2018. PMID: 29417414. doi:10.1007/s12350-018-1203-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。